 |
Prospector
Profile
07.1405
|
| |
| Protokinetix, Inc. |
NAICS |
541710 |
| Suite 1500-885 West Georgia St.
Vancouver, British Columbia, Canada V6C3E |
Description |
Biotechnology |
| (604) 687-9887 |
Employees |
0 |
|
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-1.9670 |
| |
Assets |
(mil) |
0.6130 |
| |
Liability |
(mil) |
0.4140 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Protokinetix, Inc. reported a net loss of $260,220 for the second quarter ended June 30, 2007, much lower than the $1,589,312 net loss reported during the second quarter of 2006. For the six months ended June 30, 2007, the Company had a $546,586 net loss, lower than the $1,804,359 net loss incurred during the first half of 2006. The Company's balance sheet showed an accumulated deficit of $17,403,349 and stockholder's deficit of $62,338 as of June 30, 2007. It also has strained liquidity with $380,809 in total current assets available to pay $444,082 in total current liabilities.
|
| |
|
Intellectual Property:
The Company has filed three international patent applications, including WO 2004/014928 A2; PCT Int. Appl. (2006), 87 pp. WO2006059227 A1 20060608 AN 2006:538719; and Patent application: Fr 03 May 2006, 06 03952. The Company is focused on the research and development of one primary compound known as AAGP™, which it has filed a trademark application for. [SEC Filing 10-KSB 04-17-07]
|
| |
|
Description:
The biopharmaceutical company owns the world-wide rights to a family of synthetic anti-freeze glycoproteins.
|
| |
|
Officers:
Dr. John Todd (Chair, Pres., CEO & CFO); C. Fred Whittaker (Dir.)
|
| |
|
Auditor:
Peterson Sullivan PLLC
|
| |
|
Securities:
Common Stock-Symbol PKTX.OB; OTC BB;
45,182,451 common shares outstanding as of August 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
